AP652A - Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. - Google Patents

Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. Download PDF

Info

Publication number
AP652A
AP652A APAP/P/1997/001089A AP9701089A AP652A AP 652 A AP652 A AP 652A AP 9701089 A AP9701089 A AP 9701089A AP 652 A AP652 A AP 652A
Authority
AP
ARIPO
Prior art keywords
cis
amino
zidovudine
pyrimidin
purin
Prior art date
Application number
APAP/P/1997/001089A
Other languages
English (en)
Other versions
AP9701089A0 (en
Inventor
David Walter Barry
Clair Martha Heider St
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of AP9701089A0 publication Critical patent/AP9701089A0/xx
Application granted granted Critical
Publication of AP652A publication Critical patent/AP652A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cephalosporin Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1997/001089A 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc. AP652A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
AP9701089A0 AP9701089A0 (en) 1997-10-31
AP652A true AP652A (en) 1998-06-19

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001089A AP652A (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592U89 and 3tc or Ftc.

Country Status (35)

Country Link
US (1) US6417191B1 (enExample)
EP (1) EP0817637B1 (enExample)
JP (1) JP2954357B2 (enExample)
KR (1) KR100542536B1 (enExample)
CN (1) CN1103593C (enExample)
AP (1) AP652A (enExample)
AT (1) ATE220551T1 (enExample)
AU (1) AU715213B2 (enExample)
BR (3) BRPI9607851B8 (enExample)
CA (1) CA2216634C (enExample)
CZ (1) CZ295940B6 (enExample)
DE (3) DE69622386T2 (enExample)
DK (1) DK0817637T3 (enExample)
EA (1) EA000626B3 (enExample)
EE (1) EE04047B1 (enExample)
ES (1) ES2179193T3 (enExample)
FR (1) FR05C0022I2 (enExample)
GE (1) GEP20022647B (enExample)
HU (1) HU224010B1 (enExample)
IL (1) IL117727A (enExample)
LU (1) LU91171I2 (enExample)
MX (1) MX9707316A (enExample)
MY (1) MY115461A (enExample)
NL (1) NL300195I2 (enExample)
NO (2) NO313787B1 (enExample)
NZ (1) NZ306419A (enExample)
OA (1) OA10616A (enExample)
PL (1) PL187085B1 (enExample)
PT (1) PT817637E (enExample)
RO (1) RO117995B1 (enExample)
SI (1) SI0817637T1 (enExample)
SK (1) SK283825B6 (enExample)
TR (1) TR199701074T1 (enExample)
UA (1) UA60293C2 (enExample)
WO (1) WO1996030025A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000022226A (ko) * 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
PT1583542E (pt) 2003-01-14 2008-09-17 Gilead Sciences Inc Composições e métodos para terapia de combinação antiviral
WO2004085406A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
BRPI0415533A (pt) 2003-10-24 2006-12-26 Immunaid Pty Ltd método de terapia
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
DK2435825T3 (en) 2009-05-27 2015-10-19 Biotempus Ltd Modes for medical care
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
CN118063537A (zh) 2015-09-08 2024-05-24 莫纳什大学 定向淋巴的前药
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
JP7810970B2 (ja) 2020-02-05 2026-02-04 シーポート・セラピューティクス・インコーポレイテッド 神経ステロイドの脂質プロドラッグ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
KR20000022226A (ko) 1996-06-25 2000-04-25 그레이엄 브레레톤;레슬리 에드워즈 Hiv 치료에 사용하기 위한 vx478, 지도부딘, ftc 및(또는) 3tc를 포함하는 배합물
CA2262765A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Also Published As

Publication number Publication date
CZ309097A3 (cs) 1998-05-13
BRPI9607851B8 (pt) 2019-11-05
HK1009401A1 (en) 1999-09-10
LU91171I2 (fr) 2005-07-04
DK0817637T3 (da) 2002-11-11
MY115461A (en) 2003-06-30
EA000626B3 (ru) 2016-04-29
NL300195I2 (nl) 2005-11-01
EE9700240A (et) 1998-04-15
IL117727A0 (en) 1996-07-23
MX9707316A (es) 1997-11-29
ES2179193T3 (es) 2003-01-16
CA2216634A1 (en) 1996-10-03
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
JP2954357B2 (ja) 1999-09-27
HU224010B1 (hu) 2005-04-28
SI0817637T1 (en) 2002-10-31
DE69622386T2 (de) 2003-02-13
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
NO2005014I2 (no) 2008-02-11
LU91171I9 (enExample) 2018-12-28
PL187085B1 (pl) 2004-05-31
BR9607851B1 (pt) 2009-01-13
RO117995B1 (ro) 2002-12-30
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
FR05C0022I2 (enExample) 2005-10-21
KR100542536B1 (ko) 2006-03-23
ATE220551T1 (de) 2002-08-15
KR19980703420A (ko) 1998-11-05
US6417191B1 (en) 2002-07-09
CA2216634C (en) 2004-07-20
BR9607851A (pt) 1998-07-21
SK129597A3 (en) 1998-07-08
NO313787B1 (no) 2002-12-02
DE122005000029I1 (de) 2005-10-06
IL117727A (en) 1999-11-30
OA10616A (en) 2001-03-15
CZ295940B6 (cs) 2005-12-14
EE04047B1 (et) 2003-06-16
NO2005014I1 (no) 2005-06-06
BRPI9612992B1 (pt) 2020-08-04
EA199700203A1 (ru) 1998-02-26
FR05C0022I1 (enExample) 2005-06-10
CN1103593C (zh) 2003-03-26
HUP9801571A3 (en) 2001-04-28
EA000626B1 (ru) 1999-12-29
DE122005000029I2 (de) 2006-04-27
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
CN1185110A (zh) 1998-06-17
AU5497296A (en) 1996-10-16
UA60293C2 (uk) 2003-10-15
NO974510D0 (no) 1997-09-29
JPH10511682A (ja) 1998-11-10
NO974510L (no) 1997-09-29
EP0817637B1 (en) 2002-07-17
AU715213B2 (en) 2000-01-20
PL322532A1 (en) 1998-02-02
EP0817637A1 (en) 1998-01-14

Similar Documents

Publication Publication Date Title
EP0817637B1 (en) Synergistic combinations of zidovudine, 1592u89 and 3tc
AU727983B2 (en) Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatment of HIV
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
US6486136B1 (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
US6432966B2 (en) Antiviral combinations
WO2000016779A1 (en) Antiviral combinations comprising lamivudine and abacavir
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
AU8017298A (en) Antiviral combinations containing the carbocyclic nucleoside 1592u89
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of
WO2000016754A2 (en) Antiviral combinations comprising lamivudine and lobucavir
HK1035670B (en) Antiviral combinations of lamivudine and adefovir